-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.6%
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.6%
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating)'s stock price fell 5.6% during trading on Thursday . The company traded as low as $6.41 and last traded at $6.89. 113,555 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,687,739 shares. The stock had previously closed at $7.30.
Wall Street Analyst Weigh In
A number of research firms recently commented on ESPR. Morgan Stanley boosted their target price on Esperion Therapeutics from $7.00 to $9.00 and gave the stock an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com upgraded Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.17.
Get Esperion Therapeutics alerts:Esperion Therapeutics Trading Down 5.5 %
The firm has a market cap of $508.42 million, a PE ratio of -1.47 and a beta of 0.23. The stock's 50 day moving average price is $6.74 and its 200 day moving average price is $6.96.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $0.12. The company had revenue of $18.98 million for the quarter, compared to analyst estimates of $19.83 million. Analysts forecast that Esperion Therapeutics, Inc. will post -3.65 earnings per share for the current year.Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $13,067,000. Wasatch Advisors Inc. lifted its holdings in Esperion Therapeutics by 27.6% in the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock valued at $37,804,000 after buying an additional 1,761,117 shares during the period. Millennium Management LLC lifted its holdings in Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock valued at $17,212,000 after buying an additional 1,457,952 shares during the period. Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 7,991.8% in the third quarter. Two Sigma Advisers LP now owns 1,084,300 shares of the biopharmaceutical company's stock valued at $7,265,000 after purchasing an additional 1,070,900 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Esperion Therapeutics in the second quarter valued at approximately $5,372,000. Institutional investors own 85.87% of the company's stock.
Esperion Therapeutics Company Profile
(Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Read More
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating)'s stock price fell 5.6% during trading on Thursday . The company traded as low as $6.41 and last traded at $6.89. 113,555 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,687,739 shares. The stock had previously closed at $7.30.
Esperion Therapeutics, Inc.(纳斯达克股票代码:ESPR — 获取评级)的股价在周四的交易中下跌了5.6%。该公司的交易价格低至6.41美元,最后一次交易价格为6.89美元。午盘交易中交易了113,555股,较平均交易日1,687,739股下降了93%。该股此前收于7.30美元。
Wall Street Analyst Weigh In
华尔街分析师权衡一下
A number of research firms recently commented on ESPR. Morgan Stanley boosted their target price on Esperion Therapeutics from $7.00 to $9.00 and gave the stock an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com upgraded Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.17.
许多研究公司最近对ESPR发表了评论。摩根士丹利在11月2日星期三的一份研究报告中将Esperion Therapeutics的目标价格从7.00美元上调至9.00美元,并将该股评为 “减持”。StockNews.com在11月3日星期四的一份报告中将Esperion Therapeutics的评级从 “卖出” 上调至 “持有”。两位投资分析师对该股进行了卖出评级,两位给出了持有评级,一位给出了该公司的股票买入评级。根据Marketbeat.com的数据,该公司目前的共识评级为 “持有”,平均目标价为10.17美元。
Esperion Therapeutics Trading Down 5.5 %
Esperion Therapeutics 交易下跌 5.5%
The firm has a market cap of $508.42 million, a PE ratio of -1.47 and a beta of 0.23. The stock's 50 day moving average price is $6.74 and its 200 day moving average price is $6.96.
该公司的市值为5.0842亿美元,市盈率为-1.47,beta值为0.23。该股的50天移动平均价格为6.74美元,其200天移动平均线价格为6.96美元。
Institutional Inflows and Outflows
机构流入和流出
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $13,067,000. Wasatch Advisors Inc. lifted its holdings in Esperion Therapeutics by 27.6% in the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock valued at $37,804,000 after buying an additional 1,761,117 shares during the period. Millennium Management LLC lifted its holdings in Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock valued at $17,212,000 after buying an additional 1,457,952 shares during the period. Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 7,991.8% in the third quarter. Two Sigma Advisers LP now owns 1,084,300 shares of the biopharmaceutical company's stock valued at $7,265,000 after purchasing an additional 1,070,900 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Esperion Therapeutics in the second quarter valued at approximately $5,372,000. Institutional investors own 85.87% of the company's stock.
一些机构投资者和对冲基金最近改变了他们在股票中的头寸。Ikarian Capital LLC在第二季度收购了Esperion Therapeutics的新职位,价值约13,067,000美元。Wasatch Advisors Inc.在第一季度将其在Esperion Therapeutics的持股量增加了27.6%。Wasatch Advisors Inc.在此期间又购买了1,761,117股股票后,现在拥有这家生物制药公司的8,147,380股股票,价值37,804,000美元。千禧管理有限责任公司在第二季度将其在Esperion Therapeutics的持股量增加了116.8%。Millennium Management LLC在此期间又购买了1,457,952股股票后,现在拥有这家生物制药公司的2,706,290股股票,价值17,212,000美元。Two Sigma Advisors LP在第三季度将其在Esperion Therapeutics的股份增加了7,991.8%。Two Sigma Advisors LP在上个季度又购买了1,070,900股股票后,现在拥有这家生物制药公司1,084,300股股票,价值726.5万美元。最后,Woodline Partners LP在第二季度收购了Esperion Therapeutics的新股份,价值约为53.72万美元。机构投资者拥有该公司85.87%的股票。
Esperion Therapeutics Company Profile
Esperion Thareutics 公司简介
(Get Rating)
(获取评分)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
制药公司Esperion Therapeutics, Inc开发和商业化用于治疗低密度脂蛋白胆固醇升高患者的药物。其主要候选产品是用于治疗动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症患者的NEXLETOL(bempedoic acid)和NEXLIZET(bempedoic acid)片剂。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
- 免费获取 StockNews.com 关于 Esperion Therapeutics (ESPR) 的研究报告
- Sorrento Therapeutics,Scilex:两只热门制药股正在上涨
- 阿里巴巴的大复苏即将开始吗?
- KB Home,抛售房屋建筑股票的另一个理由
- 温迪的股票上涨趋势会继续吗?
- 奥驰亚集团股票,时间不多了吗?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Esperion Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Esperion Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧